Micro Cap
Diagnostics & Research
Stocks Ranked by
Market Capitalization
| Name | Market cap | Price |
Price change % |
|
|---|---|---|---|---|
1
Biodesix
BDSX
$245M
| $245M | $23.25 | 5.95% |
|
2
Exagen
XGN
$208M
| $208M | $8.59 | 1.26% |
|
3
Burning Rock Biotech
BNR
$115M
| $115M | $10.90 | 1.36% |
|
4
Insight Molecular Diagnostics
IMDX
$96.9M
| $96.9M | $2.96 | 6.92% |
|
5
Quantum Cyber N.V.
QUCY
$70.6M
| $70.6M | $0.8400 | 7.69% |
|
6
Precipio
PRPO
$32.4M
| $32.4M | $18.10 | 6.46% |
|
7
MDxHealth
MDXH
$15.6M
| $15.6M | $0.1633 | 9.88% |
|
8
American Shared Hospital Services
AMS
$8.45M
| $8.45M | $1.27 | 0.79% |
|
9
XWELL
XWEL
$7.33M
| $7.33M | $0.6901 | 0.03% |
|
10
ENDRA Life Sciences
NDRA
$7.12M
| $7.12M | $4.75 | 2.66% |
|
11
VolitionRx Ltd
VNRX
$5.87M
| $5.87M | $0.1953 | 1.11% |
|
12
Advanced Biomed Inc
ADVB
$3.8M
| $3.8M | $2.30 | 12.9% |
|
13
iSpecimen
ISPC
$2.08M
| $2.08M | $0.8255 | 4.19% |
|
14
bioAffinity Technologies
BIAF
$1.75M
| $1.75M | $2.91 | 3.96% |
|
Micro Cap Diagnostics & Research Stocks at a Glance
Diagnostics and research companies run laboratory testing, imaging, and analytical services, and supply the instruments behind them. Testing volumes are recurring and largely non-discretionary, while research-tools demand follows pharma and academic R&D budgets.
There are 14 micro cap Diagnostics & Research stocks — companies in the Diagnostics & Research industry with a market cap under $250M — worth a combined $820M.
The largest by market cap are Biodesix (BDSX) at $245M, Exagen (XGN) at $208M and Burning Rock Biotech (BNR) at $115M.
Among institutional investors, bioAffinity Technologies (BIAF) drew the most net new fund positions in Q2 2026: 10 funds opened new positions, taking total fund holders up 7 (54%) quarter-over-quarter.
- Combined market cap: $820M across 14 stocks.
- Micro Cap: market cap under $250M.
- Largest constituent: Biodesix (BDSX), $245M market cap.
- Most net new fund positions in Q2 2026: bioAffinity Technologies (BIAF), +7 holders.
Market caps and prices updated daily; fund activity based on aggregated SEC 13F filings for Q2 2026.